<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>The milk-alkali syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">The milk-alkali syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">The milk-alkali syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan S L Yu, MB, BChir</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jason R Stubbs, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Emmett, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The milk-alkali syndrome consists of the triad of hypercalcemia, metabolic alkalosis, and acute kidney injury associated with the ingestion of large amounts of calcium and absorbable alkali. The syndrome was originally described in association with the use of milk and <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> for the treatment of peptic ulcer disease [<a href="#rid1">1</a>]. Once a classic cause of hypercalcemia, the milk-alkali syndrome virtually disappeared with the advent of new therapies of peptic ulcer disease and, by 1985, was considered the cause of less than one percent of cases of hypercalcemia [<a href="#rid2">2</a>].</p><p>However, there has since been a resurgence of this disorder, and it may account for up to 12 percent of cases, making it the third leading cause of hypercalcemia behind primary hyperparathyroidism and malignancy [<a href="#rid3">3,4</a>]. (See  <a class="medical medical_review" href="/z/d/html/839.html" rel="external">"Etiology of hypercalcemia"</a>.)</p><p>Three factors are responsible for this increase in incidence:</p><p class="bulletIndent1"><span class="glyph">●</span>The emphasis on calcium therapy for the prevention and treatment of osteoporosis</p><p class="bulletIndent1"><span class="glyph">●</span>Readily available over-the-counter <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a> preparations</p><p class="bulletIndent1"><span class="glyph">●</span>The use of <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a> to minimize secondary hyperparathyroidism in patients with chronic kidney disease (see  <a class="medical medical_review" href="/z/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease"</a>)</p><p></p><p>This topic reviews the pathogenesis, clinical presentation, diagnosis, and treatment of the milk-alkali syndrome. Other causes of hypercalcemia and alkalosis, and the treatment of these disorders, are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/839.html" rel="external">"Etiology of hypercalcemia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/836.html" rel="external">"Diagnostic approach to hypercalcemia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2331.html" rel="external">"Causes of metabolic alkalosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/850.html" rel="external">"Treatment of hypercalcemia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2345.html" rel="external">"Treatment of metabolic alkalosis"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">HISTORICAL PERSPECTIVE</span><span class="headingEndMark"> — </span>In 1915, Bertram Sippy introduced an antacid regimen designed to neutralize gastric acidity and promote the healing of peptic ulcer disease [<a href="#rid5">5</a>]. The regimen included the hourly administration of milk or cream with Sippy powders (a powder containing 600 mg of <a class="drug drug_general" data-topicid="114387" href="/z/d/drug information/114387.html" rel="external">magnesium carbonate</a> and 600 mg <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> alternating with a powder containing 600 mg of bismuth subcarbonate and 1200 to 1800 mg of sodium bicarbonate). Toxic reactions characterized by alkalosis and kidney injury were noted shortly thereafter, but the plasma calcium concentration was not measured [<a href="#rid6">6</a>]. In 1936, a report associated hypercalcemia with the alkalosis and kidney injury in patients treated with the Sippy regimen [<a href="#rid1">1</a>].</p><p>Despite these observations, therapy of peptic ulcer disease continued to include the administration of large doses (20 to 60 gm per day) of <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a>, and less acute and more frequent cases were reported. Most cases were middle-aged men, the group with the highest incidence of peptic ulcer disease.</p><p class="headingAnchor" id="H1941291"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The milk-alkali syndrome is caused by the ingestion of large amounts of calcium in conjunction with absorbable alkali. However, the fraction of the population at risk who develop sustained hypercalcemia, metabolic alkalosis, and kidney disease is relatively small. In one series of 1350 patients treated with the Sippy regimen, approximately 8 percent were affected [<a href="#rid7">7</a>]. In another study, 297 heart and lung transplant recipients were prescribed large doses of <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a> as prophylaxis for adverse effects of glucocorticoid immunosuppression. Sixty-five patients developed hypercalcemia; 31 were alkalotic at the time of the hypercalcemia, and 37 had an impairment in kidney function [<a href="#rid8">8</a>].</p><p>It is probable that normal kidney function and the suppression of calcitriol production allow maintenance of calcium and acid-base balance in most individuals exposed to large doses of calcium and alkali. Under normal circumstances, the fractional intestinal absorption of filtered calcium declines markedly as calcitriol levels fall, and calcium intakes exceeding 4 grams per day are necessary to achieve normal serum levels in the absence of calcitriol. However, net calcium absorption increases markedly when intake is increased to 10 to 15 grams per day despite suppression of calcitriol [<a href="#rid9">9</a>]. In addition, some individuals may not adequately suppress calcitriol in response to large doses of calcium, resulting sequentially in hyperabsorption of calcium and hypercalcemia [<a href="#rid10">10</a>]. (See <a class="local">'Possible role of calcitriol'</a> below.)</p><p>Although the mechanisms that initiate hypercalcemia are incompletely understood, clinical studies suggest that hypercalcemia underlies the subsequent metabolic derangements including alkalosis and acute kidney injury [<a href="#rid11">11</a>].</p><p>Hypercalcemia produces the following effects in the kidney:</p><p class="bulletIndent1"><span class="glyph">●</span>Vasoconstriction, which decreases the glomerular filtration rate (GFR).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activation of the calcium-sensing receptor in the medullary thick ascending limb, which inhibits the Na-K-2Cl cotransporter causing natriuresis. (See  <a class="medical medical_review" href="/z/d/html/838.html" rel="external">"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia", section on 'Urine calcium excretion'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blockade of antidiuretic hormone (ADH)-dependent water reabsorption in the collecting duct. (See  <a class="medical medical_review" href="/z/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes", section on 'Hypercalcemia'</a>.)</p><p></p><p>The calcium-induced diuresis results in volume depletion, which stimulates the renal tubular absorption of bicarbonate. The combined effects of increased alkali intake, volume depletion, and decreased GFR lead to metabolic alkalosis.</p><p>Alkalosis may contribute to the maintenance of both volume depletion (by enhancing the activity of the calcium-sensing receptor) and hypercalcemia (by increasing calcium reabsorption in the distal tubule via the pH-sensitive calcium channel, the transient receptor potential vanilloid member 5 [TRPV5]) [<a href="#rid12">12,13</a>]. Volume depletion due to vomiting or diuretics will also worsen the hypercalcemia and alkalosis.</p><p>Marked hypercalcemia can lead to an acute clinical presentation. On the other hand, prolonged or intermittent mild hypercalcemia in conjunction with metabolic alkalosis sets the stage for the development of nephrocalcinosis and chronic kidney disease.</p><p class="headingAnchor" id="H1941314"><span class="h2">Extrarenal factors</span><span class="headingEndMark"> — </span>Extrarenal factors that may contribute to the initial development of hypercalcemia include decreased bone buffering and decreased suppression of calcitriol.</p><p class="headingAnchor" id="H1941320"><span class="h3">Decreased bone buffering</span><span class="headingEndMark"> — </span>Bone provides the chief reservoir for buffering excess calcium. Older patients have a reduced capacity for bone buffering, which may cause them to be at higher risk for hypercalcemia following the ingestion of calcium-containing supplements [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H1941358"><span class="h3">Possible role of calcitriol</span><span class="headingEndMark"> — </span>The following observations indicate that some individuals may not suppress calcitriol levels in response to large doses of <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>Experimental studies show that not all normal individuals fed <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a> suppress calcitriol levels to the same extent, with hormone levels remaining well within the normal range in some [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The suppression of calcitriol levels by oral <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a> administration in patients with idiopathic hypercalciuria is transient, with the levels returning to the normal range after two weeks of continued ingestion [<a href="#rid15">15</a>].</p><p></p><p>The hypothesis that a lack of suppression of calcitriol synthesis is an important determinant of susceptibility to the milk-alkali syndrome has not been formally tested. In published reports describing biochemical parameters in patients presenting with milk-alkali syndrome, plasma calcitriol concentrations appear to be quite variable and demonstrate no consistent pattern [<a href="#rid16">16,17</a>].</p><p>This issue assumes more importance in light of the emphasis on <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a> intake for the treatment and prevention of osteoporosis. While recommended doses are only 1.2 g per day, it is likely that some patients, unless otherwise instructed, take higher doses. In the absence of a source of phosphate such as milk, calcium carbonate may produce mild hypophosphatemia, which directly increases the synthesis of calcitriol. Increased intake of calcium and alkali in association with high or even normal levels of calcitriol may predispose certain individuals to mild intermittent hypercalcemia at doses lower than those previously reported. Concurrent therapy with vitamin D, for either osteoporosis or secondary hyperparathyroidism in chronic kidney disease, makes the development of hypercalcemia much more likely. Individuals with mild chronic kidney disease, volume depletion, and those treated with a thiazide diuretic (which directly reduces calcium excretion) are also likely to be at increased risk. (See  <a class="medical medical_review" href="/z/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis"</a> and  <a class="medical medical_review" href="/z/d/html/1964.html" rel="external">"Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis"</a> and  <a class="medical medical_review" href="/z/d/html/2340.html" rel="external">"Diuretics and calcium balance"</a>.)</p><p>Pregnant women may have elevated calcitriol levels and increased calcium absorption and may also be predisposed to hypovolemia and metabolic alkalosis due to vomiting. Numerous cases of milk-alkali syndrome have been reported in pregnant women [<a href="#rid18">18-20</a>], which suggests that oral <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a> should be used with caution during pregnancy (eg, for the relief of symptoms of reflux).</p><p class="headingAnchor" id="H1941396"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Patients who appear to be at higher risk for milk-alkali syndrome include older individuals, those susceptible to volume depletion (including patients on thiazide diuretics), and those on medications that reduce the GFR, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or nonsteroidal antiinflammatory drugs [<a href="#rid13">13</a>]. Patients with chronic kidney disease [<a href="#rid4">4</a>], including patients on dialysis, and pregnant women are also at increased risk. A less common risk factor for milk-alkali syndrome is nicotine-substitute chewing gum, which can provide a significant calcium load when utilized in large quantities [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The milk-alkali syndrome can present in a variety of ways that, in part, depend upon the amount and duration of the calcium and alkali ingestion, as well as the presence of risk factors such as thiazide diuretic use and volume depletion.</p><p>Most patients with the milk-alkali syndrome are women who take <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a>, often to prevent or treat osteoporosis. They are often asymptomatic and the hypercalcemia, alkalosis, and kidney function impairment are discovered incidentally. (See <a class="local">'Modern presentation'</a> below.)</p><p>The syndrome can also be seen in patients taking calcium-containing over-the-counter antacid medications, and in patients with chronic kidney disease who are prescribed <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a> to treat secondary hyperparathyroidism. (See  <a class="medical medical_review" href="/z/d/html/1964.html" rel="external">"Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease"</a>.)</p><p>Historically, patients presented with symptoms of acute or chronic hypercalcemia (eg, nausea, vomiting, weakness, altered sensorium, and pruritus) and, depending upon the duration of hypercalcemia, kidney function impairment that did not always resolve after normalization of the plasma calcium. (See <a class="local">'Classical presentation'</a> below.)</p><p class="headingAnchor" id="H1941786"><span class="h2">Modern presentation</span><span class="headingEndMark"> — </span>The incidence of the milk-alkali syndrome increased during the 1990s [<a href="#rid3">3,4,18,22</a>]. One study found that the milk-alkali syndrome accounted for two percent of hospitalized patients with hypercalcemia between 1985 and 1989, as compared with 12 percent between 1990 and 1993 [<a href="#rid3">3</a>]. In another study, milk-alkali syndrome accounted for 8.8 percent of hypercalcemia cases between 1998 and 2003 [<a href="#rid4">4</a>].</p><p>The majority of patients who now present with milk-alkali syndrome are women, and <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a> is the predominant source of calcium and alkali intake. Betel nut chewing, which occurs in Asia and the South Pacific, can also cause the syndrome [<a href="#rid23">23,24</a>]. Because these nuts are bitter, they are wrapped in a compound containing calcium hydroxide, which is eventually converted to calcium carbonate.</p><p>The modern presentation differs from the historical presentation in the following ways:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients are often asymptomatic and the finding of hypercalcemia, alkalosis, and kidney function impairment is an <strong>incidental discovery</strong>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypophosphatemia is common, reflecting both the absence of a phosphate load in conjunction with the calcium load and the phosphate-binding properties of <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a>. Historically, milk supplied the calcium load in patients with the milk-alkali syndrome, and milk contains a large amount of phosphate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypomagnesemia is common at presentation [<a href="#rid4">4</a>], likely due to the ability of hypercalcemia to inhibit magnesium reabsorption by the renal tubule.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intact parathyroid hormone (PTH) levels are generally reduced. This is an important feature that can help distinguish the milk-alkali syndrome from primary hyperparathyroidism [<a href="#rid4">4,25</a>]. In addition, hypocalcemia may develop after therapy of the milk-alkali syndrome, possibly reflecting the combination of PTH suppression with the cessation of the calcium source.</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Classical presentation</span><span class="headingEndMark"> — </span>Three clinical syndromes were recognized in original descriptions [<a href="#rid26">26</a>]. These forms of symptomatic hypercalcemia can still be seen, albeit rarely, in the modern era:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute – The acute or "toxemic" form occurred after approximately one week of treatment [<a href="#rid27">27</a>]. The symptoms were those of acute hypercalcemia and included nausea, vomiting, weakness, and mental changes with psychosis or depressed sensorium (see  <a class="medical medical_review" href="/z/d/html/832.html" rel="external">"Clinical manifestations of hypercalcemia"</a>). There was also severe metabolic alkalosis, a normal to elevated plasma phosphate concentration, and acute kidney injury. Withdrawal of milk and alkali led to rapid relief of symptoms and the return of normal kidney function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic – In the chronic form (also called Burnett's syndrome), patients presented after a long history of high milk/alkali intake with symptoms of chronic hypercalcemia, such as polyuria, polydipsia, muscle aches, and pruritus [<a href="#rid28">28-30</a>]. Frequently, there was evidence of metastatic calcifications, including band keratopathy and nephrocalcinosis. Laboratory abnormalities were similar to those in the acute syndrome, but the response to withdrawal of milk and alkali was quite different. The muscle aches and pruritus improved slowly as the plasma calcium concentration slowly normalized. However, there was usually minimal or no improvement in kidney function, as many patients had developed chronic kidney disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subacute or intermediate – In the subacute form (also called Cope's syndrome), patients were usually seen during therapy with milk and alkali that had been taken intermittently for years [<a href="#rid31">31</a>]. Affected patients had symptoms of both acute and chronic hypercalcemia and responded to medication withdrawal with gradual improvement. Kidney function remained mildly impaired in some cases.</p><p></p><p class="headingAnchor" id="H69902931"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>In a patient with hypercalcemia, alkalosis, and kidney function impairment, the diagnosis of milk-alkali syndrome is based upon the history of ingestion of calcium-rich medications and the exclusion of other causes of hypercalcemia. A thorough history is critical in identifying potential extrinsic sources of calcium or the use of vitamin D preparations that may increase intestinal calcium absorption. The diagnostic approach to hypercalcemia is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/836.html" rel="external">"Diagnostic approach to hypercalcemia"</a>.)</p><p class="headingAnchor" id="H69903554"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Withdrawal of the offending agent (eg, <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a>) and treatment with isotonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> usually produces clinical improvement and rapid resolution of the hypercalcemia and metabolic alkalosis. In more severe cases, concurrent <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> therapy can be added to induce further urinary calcium excretion. (See  <a class="medical medical_review" href="/z/d/html/850.html" rel="external">"Treatment of hypercalcemia"</a> and  <a class="medical medical_review" href="/z/d/html/2345.html" rel="external">"Treatment of metabolic alkalosis"</a>.)</p><p>Hypocalcemia often occurs transiently during treatment with <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a>, accompanied by a rebound rise in parathyroid hormone (PTH) to supranormal levels; this phenomenon is unique to the milk-alkali syndrome [<a href="#rid3">3</a>]. This may be because, with other etiologies of hypercalcemia (eg, primary hyperparathyroidism or malignancy), the stimulus to calcium retention persists even after acute treatment of the hypercalcemia. By contrast, in milk-alkali syndrome, cessation of calcium and alkali ingestion immediately removes the hypercalcemic stimulus while suppressed PTH levels are slower to respond. For the same reason, bisphosphonates, which cause a prolonged suppression of the serum calcium, can produce hypocalcemia in patients with the milk-alkali syndrome and should be avoided [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H4158473743"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109733.html" rel="external">"Society guideline links: Fluid and electrolyte disorders in adults"</a>.)</p><p class="headingAnchor" id="H69903561"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– The milk-alkali syndrome consists of the triad of hypercalcemia, metabolic alkalosis, and kidney function impairment associated with the ingestion of calcium and absorbable alkali. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– The milk-alkali syndrome starts with the development of hypercalcemia. Hypercalcemia causes a vasoconstriction-induced decline in glomerular filtration rate (GFR), activation of the calcium-sensing receptor in the medullary thick ascending limb, and blockade of antidiuretic hormone (ADH)-mediated water reabsorption in the collecting duct, resulting in natriuresis and volume depletion. The combined effects of increased alkali intake, decreased GFR, and volume depletion lead to metabolic alkalosis. Extrarenal mechanisms that may contribute to hypercalcemia in susceptible individuals include decreased bone buffering capacity and insufficient suppression of calcitriol. (See <a class="local">'Pathogenesis'</a> above and <a class="local">'Decreased bone buffering'</a> above and <a class="local">'Possible role of calcitriol'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors </strong>– Patients at higher risk for the development of the milk-alkali syndrome include older individuals, those at risk for volume depletion (including patients on thiazide diuretics), and those taking medications that reduce the GFR, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and nonsteroidal antiinflammatory drugs. Pregnant women may also be at higher risk. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– Most patients with the milk-alkali syndrome are women who take <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a>, often to prevent or treat osteoporosis. They are often asymptomatic and the hypercalcemia, alkalosis, and kidney function impairment are discovered incidentally. The syndrome can also be seen in patients taking calcium-containing over-the-counter antacid medications, and in patients with chronic kidney disease who are prescribed calcium carbonate to treat secondary hyperparathyroidism. Historically, patients presented with symptoms of acute or chronic hypercalcemia (eg, nausea, vomiting, weakness, altered sensorium, and pruritus) and, depending upon the duration of hypercalcemia, kidney function impairment that did not always resolve after normalization of the plasma calcium. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of milk-alkali syndrome is based upon the history of ingestion of calcium-rich medications and the exclusion of other causes of hypercalcemia. (See <a class="local">'Diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/836.html" rel="external">"Diagnostic approach to hypercalcemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– Withdrawal of the offending agent (eg, <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a>) and treatment with isotonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> usually produces clinical improvement and rapid resolution of the hypercalcemia and metabolic alkalosis. In more severe cases, concurrent <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> therapy can be added to induce further urinary calcium excretion. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/z/d/html/850.html" rel="external">"Treatment of hypercalcemia"</a> and  <a class="medical medical_review" href="/z/d/html/2345.html" rel="external">"Treatment of metabolic alkalosis"</a>.)</p><p></p><p class="headingAnchor" id="H524418837"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Zalman S Agus, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cope CL. Base changes in the alkalosis produced by the treatment of gastric ulcer with alkalies. Clin Sci 1936; 2:287.</a></li><li><a class="nounderline abstract_t">Jamieson MJ. Hypercalcaemia. Br Med J (Clin Res Ed) 1985; 290:378.</a></li><li><a class="nounderline abstract_t">Beall DP, Scofield RH. Milk-alkali syndrome associated with calcium carbonate consumption. Report of 7 patients with parathyroid hormone levels and an estimate of prevalence among patients hospitalized with hypercalcemia. Medicine (Baltimore) 1995; 74:89.</a></li><li><a class="nounderline abstract_t">Picolos MK, Lavis VR, Orlander PR. Milk-alkali syndrome is a major cause of hypercalcaemia among non-end-stage renal disease (non-ESRD) inpatients. Clin Endocrinol (Oxf) 2005; 63:566.</a></li><li><a class="nounderline abstract_t">Sippy BW. Gastric and duodenal ulcer: Medical cure by an efficient removal of gastric juice corrosion. JAMA 1915; 64:1625.</a></li><li><a class="nounderline abstract_t">Hardt LL, Rivers AB. Toxic manifestations following the alkaline treatment of peptic ulcer. Arch Intern Med 1923; 31:171.</a></li><li><a class="nounderline abstract_t">Kirsner JB, Palmer WL. Alkalosis complicating the Sippy treatment of peptic ulcer. Arch Intern Med 1942; 69:789.</a></li><li><a class="nounderline abstract_t">Kapsner P, Langsdorf L, Marcus R, et al. Milk-alkali syndrome in patients treated with calcium carbonate after cardiac transplantation. Arch Intern Med 1986; 146:1965.</a></li><li><a class="nounderline abstract_t">Bronner F. Mechanisms of intestinal calcium absorption. J Cell Biochem 2003; 88:387.</a></li><li><a class="nounderline abstract_t">Felsenfeld AJ, Levine BS. Milk alkali syndrome and the dynamics of calcium homeostasis. Clin J Am Soc Nephrol 2006; 1:641.</a></li><li><a class="nounderline abstract_t">McMillan DE, Freeman RB. The milk alkali syndrome: a study of the acute disorder with comments on the development of the chronic condition. Medicine (Baltimore) 1965; 44:485.</a></li><li><a class="nounderline abstract_t">Sutton RA, Wong NL, Dirks JH. Effects of metabolic acidosis and alkalosis on sodium and calcium transport in the dog kidney. Kidney Int 1979; 15:520.</a></li><li><a class="nounderline abstract_t">Patel AM, Goldfarb S. Got calcium? Welcome to the calcium-alkali syndrome. J Am Soc Nephrol 2010; 21:1440.</a></li><li><a class="nounderline abstract_t">Adams ND, Gray RW, Lemann J Jr. The effects of oral CaCO3 loading and dietary calcium deprivation on plasma 1,25-dihydroxyvitamin D concentrations in healthy adults. J Clin Endocrinol Metab 1979; 48:1008.</a></li><li><a class="nounderline abstract_t">Broadus AE, Insogna KL, Lang R, et al. Evidence for disordered control of 1,25-dihydroxyvitamin D production in absorptive hypercalciuria. N Engl J Med 1984; 311:73.</a></li><li><a class="nounderline abstract_t">Dorsch TR. The milk-alkali syndrome, vitamin D, and parathyroid hormone. Ann Intern Med 1986; 105:800.</a></li><li><a class="nounderline abstract_t">Abreo K, Adlakha A, Kilpatrick S, et al. The milk-alkali syndrome. A reversible form of acute renal failure. Arch Intern Med 1993; 153:1005.</a></li><li><a class="nounderline abstract_t">Picolos MK, Sims CR, Mastrobattista JM, et al. Milk-alkali syndrome in pregnancy. Obstet Gynecol 2004; 104:1201.</a></li><li><a class="nounderline abstract_t">Ennen CS, Magann EF. Milk-alkali syndrome presenting as acute renal insufficiency during pregnancy. Obstet Gynecol 2006; 108:785.</a></li><li><a class="nounderline abstract_t">Kolnick L, Harris BD, Choma DP, Choma NN. Hypercalcemia in pregnancy: a case of milk-alkali syndrome. J Gen Intern Med 2011; 26:939.</a></li><li><a class="nounderline abstract_t">Swanson CM, Mackey PA, Westphal SA, Argueta R. Nicotine-substitute gum-induced milk alkali syndrome: a look at unexpected sources of calcium. Endocr Pract 2013; 19:142.</a></li><li><a class="nounderline abstract_t">McGuinness B, Logan JI. Milk alkali syndrome. Ulster Med J 2002; 71:132.</a></li><li><a class="nounderline abstract_t">Lin SH, Lin YF, Cheema-Dhadli S, et al. Hypercalcaemia and metabolic alkalosis with betel nut chewing: emphasis on its integrative pathophysiology. Nephrol Dial Transplant 2002; 17:708.</a></li><li><a class="nounderline abstract_t">Allen SE, Singh S, Robertson WG. The increased risk of urinary stone disease in betel quid chewers. Urol Res 2006; 34:239.</a></li><li><a class="nounderline abstract_t">Medarov BI. Milk-alkali syndrome. Mayo Clin Proc 2009; 84:261.</a></li><li><a class="nounderline abstract_t">Orwoll ES. The milk-alkali syndrome: current concepts. Ann Intern Med 1982; 97:242.</a></li><li><a class="nounderline abstract_t">Cooke AM. Alkalosis occurring in the alkaline treatment of peptic ulcers. Quart J Med 1932; 25:527.</a></li><li><a class="nounderline abstract_t">BURNETT CH, COMMONS RR. Hypercalcemia without hypercalcuria or hypophosphatemia, calcinosis and renal insufficiency; a syndrome following prolonged intake of milk and alkali. N Engl J Med 1949; 240:787.</a></li><li><a class="nounderline abstract_t">Junor BJ, Catto GR. Renal biopsy in the milk-alkali syndrome. J Clin Pathol 1976; 29:1074.</a></li><li><a class="nounderline abstract_t">Kallmeyer JC, Funston MR. The milk-alkali syndrome. A case report. S Afr Med J 1983; 64:287.</a></li><li><a class="nounderline abstract_t">PUNSAR S, SOMER T. The milk-alkali syndrome. A report of three illustrative cases and a review of the literature. Acta Med Scand 1963; 173:435.</a></li></ol></div><div id="topicVersionRevision">Topic 827 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Base changes in the alkalosis produced by the treatment of gastric ulcer with alkalies</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3917827" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hypercalcaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7891547" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Milk-alkali syndrome associated with calcium carbonate consumption. Report of 7 patients with parathyroid hormone levels and an estimate of prevalence among patients hospitalized with hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16268810" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Milk-alkali syndrome is a major cause of hypercalcaemia among non-end-stage renal disease (non-ESRD) inpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Gastric and duodenal ulcer: Medical cure by an efficient removal of gastric juice corrosion</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Toxic manifestations following the alkaline treatment of peptic ulcer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Alkalosis complicating the Sippy treatment of peptic ulcer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3532984" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Milk-alkali syndrome in patients treated with calcium carbonate after cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12520541" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mechanisms of intestinal calcium absorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699269" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Milk alkali syndrome and the dynamics of calcium homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5851468" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The milk alkali syndrome: a study of the acute disorder with comments on the development of the chronic condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/480784" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effects of metabolic acidosis and alkalosis on sodium and calcium transport in the dog kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20413609" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Got calcium? Welcome to the calcium-alkali syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/571872" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The effects of oral CaCO3 loading and dietary calcium deprivation on plasma 1,25-dihydroxyvitamin D concentrations in healthy adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6330548" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Evidence for disordered control of 1,25-dihydroxyvitamin D production in absorptive hypercalciuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3767165" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The milk-alkali syndrome, vitamin D, and parathyroid hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8481062" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The milk-alkali syndrome. A reversible form of acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15516453" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Milk-alkali syndrome in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17018502" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Milk-alkali syndrome presenting as acute renal insufficiency during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21347876" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hypercalcemia in pregnancy: a case of milk-alkali syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23807522" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Nicotine-substitute gum-induced milk alkali syndrome: a look at unexpected sources of calcium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12513010" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Milk alkali syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11981051" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hypercalcaemia and metabolic alkalosis with betel nut chewing: emphasis on its integrative pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16534642" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The increased risk of urinary stone disease in betel quid chewers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19252114" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Milk-alkali syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7049033" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The milk-alkali syndrome: current concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Alkalosis occurring in the alkaline treatment of peptic ulcers</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18126919" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hypercalcemia without hypercalcuria or hypophosphatemia, calcinosis and renal insufficiency; a syndrome following prolonged intake of milk and alkali.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1010876" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Renal biopsy in the milk-alkali syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6688308" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The milk-alkali syndrome. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13972538" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The milk-alkali syndrome. A report of three illustrative cases and a review of the literature.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
